CBM effectively prevented the inhibition of COX-1, COX-2, AKR1C1, and AKR1C2 while retaining AKR1C3 inhibition, making it a valuable molecular probe for studying AKR1C3’s role in breast cancer signaling and proliferation (Byrns and Penning, 2009). This evidence concerns the gene AKR1C3 and breast carcinoma.